Respiratory syncytial virus vaccine: Uses, Dosage,...

This information is not country-specific. Please refer to the Hong Kong prescribing information.

Generic Medicine Info

Indications and Dosage

Intramuscular
Active immunisation against respiratory syncytial virus

Adult: Abrysvo or Arexvy For the prevention of lower respiratory tract disease: ≥60 years 0.5 mL as a single dose via IM inj preferably in the deltoid muscle. Use must be in accordance with the official recommendations. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).

Intramuscular
Active immunisation against respiratory syncytial virus

Adult: Abrysvo For the prevention of lower respiratory tract disease in pregnant patients at 32 through 36 weeks gestational age and severe lower respiratory tract disease in infants from birth through 6 months of age: 0.5 mL as a single dose via IM inj preferably in the deltoid muscle. Use must be in accordance with the official recommendations. Treatment and dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).

What are the brands available for Respiratory syncytial virus vaccine in Hong Kong?

Arexvy

Reconstitution

Arexvy Withdraw content from the suspension vial then add into the vial containing the powder. Gently swirl until powder is dissolved. Abrysvo Inject the entire contents of the syringe into the vial. Hold the plunger rod down then gently swirl the vial until powder dissolves. Do not shake. Invert the vial then slowly withdraw the entire content into the syringe (approx 0.5 mL).

Contraindications

Hypersensitivity.

Special Precautions

Patient with thrombocytopenia or any coagulation disorder. Immunocompromised patients. Defer administration in patients with moderate to severe acute illness (with or without fever); vaccination may be given in patients with mild acute illness. Respiratory syncytial virus vaccine is available in multiple formulations, refer to specific product guidelines prior to administration. Pregnancy and lactation.

Adverse Reactions

Significant: Hypersensitivity and anaphylactoid reactions; Guillain-Barre syndrome or inflammatory neurologic events, syncope; bleeding/haematoma (after IM inj in patients with bleeding disorders); shoulder injury (e.g. shoulder bursitis, tendinitis) following improper vaccine administration.
Blood and lymphatic system disorders: Lymphadenopathy.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain.
General disorders and administration site conditions: Inj site pain, erythema, swelling or pruritus; fever, chills, fatigue, pain, malaise.
Musculoskeletal and connective tissue disorders: Myalgia, arthralgia.
Nervous system disorders: Headache.

Pregnancy Category (US FDA)

IM: Z (Higher rate of preterm birth was observed in clinical trials. Consult product literature and clinical guidelines for specific recommendations when clinically required during pregnancy.)

Monitoring Parameters

Monitor for anaphylaxis and syncope 15 minutes following administration.

Drug Interactions

Immune response to the vaccine may be decreased by immunosuppressive therapies. May cause bleeding or bruising after IM administration in patients receiving anticoagulant therapy.

Action

Description:
Mechanism of Action: Respiratory syncytial virus vaccine induces an active immune response against respiratory syncytial virus prefusion F (RSVPre) and respiratory syncytial virus prefusion F3 (RSVPre3) glycoprotein to protect against RSV-A and/or B-associated lower respiratory tract disease.
Duration: At least 2 RSV seasons.

Storage

Store between 2-8°C. Do not freeze. Protect from light.

MIMS Class

Vaccines, Antisera & Immunologicals

References

Abrysvo Injection, Powder, Lyophilized, for Solution (Pfizer Laboratories Diy Pfizer Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 07/02/2025.

Abrysvo Powder and Solvent for Solution for Injection (Pfizer Limited). MHRA. https://products.mhra.gov.uk. Accessed 07/02/2025.

Abrysvo Powder and Solvent for Solution for Injection (Pfizer Pte Ltd). MIMS Singapore. http://www.mims.com/singapore. Accessed 07/02/2025.

Anon. Respiratory Syncytial Virus Vaccine, Adjuvanted. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 07/02/2025.

Anon. Respiratory Syncytial Virus Vaccine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 07/02/2025.

Arexvy Powder and Suspension for Suspension for Injection (GlaxoSmithKline Pharmaceutical Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 07/02/2025.

Arexvy Powder and Suspension for Suspension for Injection (GlaxoSmithKline UK Limited). MHRA. https://products.mhra.gov.uk. Accessed 07/02/2025.

Arexvy Vaccine Recombinant, Adjuvanted (GlaxoSmithKline Biologicals SA). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 07/02/2025.

Brayfield A, Cadart C (eds). Respiratory Syncytial Virus Vaccine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/02/2025.

GlaxoSmithKline NZ Limited. Arexvy 120 micrograms Powder and Suspension for Suspension for Injection data sheet 02 May 2024. Medsafe. http://www.medsafe.govt.nz. Accessed 07/02/2025.

Respiratory Syncytial Virus Vaccine (Recombinant [Adjuvanted]). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 07/02/2025.

Respiratory Syncytial Virus Vaccine (Recombinant). UpToDate Lexidrug, Lexi-Drugs Multinational Online. Waltham, MA. UpToDate, Inc. https://online.lexi.com. Accessed 07/02/2025.

Respiratory Syncytial Virus Vaccine. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 07/02/2025.

Disclaimer: This information is independently developed by MIMS based on Respiratory syncytial virus vaccine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2025 MIMS. All rights reserved. Powered by MIMS.com